Lannett Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANNETT
LANNETT has one hundred and thirty-four approved drugs.
There are two tentative approvals on LANNETT drugs.
Summary for Lannett
| US Patents: | 0 |
| Tradenames: | 99 |
| Ingredients: | 95 |
| NDAs: | 134 |
| Patent Litigation for Lannett: | See patent lawsuits for Lannett |
| PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | TRICHLOREX | trichlormethiazide | TABLET;ORAL | 085630-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lannett | GLUTETHIMIDE | glutethimide | TABLET;ORAL | 085571-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lannett | SECOBARBITAL SODIUM | secobarbital sodium | CAPSULE;ORAL | 085909-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lannett Co Inc | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 212997-003 | Jul 24, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lannett | DEXTROAMPHETAMINE SULFATE | dextroamphetamine sulfate | TABLET;ORAL | 085652-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-003 | May 27, 2003 | 6,344,215 | ⤷ Start Trial |
| Lannett | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-002 | Jun 19, 2003 | 6,344,215 | ⤷ Start Trial |
| Lannett | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-004 | Feb 19, 2006 | 6,344,215 | ⤷ Start Trial |
| Lannett | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-001 | Apr 3, 2001 | 6,344,215 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
